Kestra Medical preliminary Q2 FY26 revenue up 52% YoY to $22.2-22.6M; gross margin improves to 50.0%

KESTRA MEDICAL TECHNOLOGIES, LTD.

2025-Q2 EPS reported -$1.14 revenue$41,937,000

Revenue expected $22.2-$22.6M vs $14.7M prior year (+52% at midpoint).
Gross profit $11.0-$11.4M (prior $5.8M); gross margin 50.0% vs 39.6%.
Loss from operations $31.6-$32.0M (prior year $19.1M), reflecting investment in growth.
Cash and equivalents ~$175M.
CEO cites commercial momentum and positive unit economics.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.